Details for Patent: 10,933,046

✉ Email this page to a colleague

Which drugs does patent 10,933,046 protect, and when does it expire?

Patent 10,933,046 protects EPSOLAY and is included in one NDA.

This patent has twelve patent family members in two countries.

Summary for Patent: 10,933,046

Patent landscape, scope, and claims:

Title:	Method for treatment of rosacea in patients aged 65 years and older
Abstract:	A regimen for the therapeutic treatment of rosacea in subjects aged 65 years and older, the regimen comprising topically applying to the skin of a subject aged 65 years and older in need of said treatment a pharmaceutical composition, the pharmaceutical composition comprising about 1% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient, wherein the benzoyl peroxide is the only active ingredient in said pharmaceutical composition, wherein said pharmaceutical composition is applied once daily for a period of at least about 2 weeks, to achieve, in a group of such subjects, a success rate of at least about 15%, wherein the success rate is defined as the number of subjects achieving clear or almost clear skin on the investor global assessment (IGA) scale after treatment with the pharmaceutical composition.
Inventor(s):	Toledano; Ofer (Kfar Saba, IL), Levy-Hacham; Ofra (Ness Ziona, IL), Nov; Ori (Tarum, IL), Ram; Vered (Rehovot, IL)
Assignee:	SOL-GEL TECHNOLOGIES, LTD. (Ness Ziona, IL)
Application Number:	16/794,839
Patent Claim Types: see list of patent claims	Use; Composition; Formulation;
More… ↓ ⤷ Subscribe

Drugs Protected by US Patent 10,933,046

Glossary

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Galderma Labs Lp	EPSOLAY	benzoyl peroxide	CREAM;TOPICAL	214510-001	Apr 22, 2022		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe	Y			TOPICAL TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA IN ADULTS 65 YEARS OF AGE AND OLDER	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 10,933,046

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	3130362	⤷ Subscribe
Canada	3130437	⤷ Subscribe
Canada	3130439	⤷ Subscribe
Canada	3130441	⤷ Subscribe
World Intellectual Property Organization (WIPO)	2020170029	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.